Research programme: tetracyclic tetrahydrofuran derivatives - Johnson and Johnson
Alternative Names: JNJ 17297709Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Janssen-Cilag; Johnson & Johnson
- Developer Janssen-Cilag
- Class Furans
- Mechanism of Action Serotonin 2C receptor antagonists; Serotonin 5-HT2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders; Major depressive disorder
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anxiety-disorders in Spain
- 16 Jul 2016 No recent reports of development identified for preclinical development in Major depressive disorder in Spain
- 19 Sep 2002 Preclinical trials in Anxiety disorders in Spain (unspecified route)